Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer

Table 2 Univariate and multiple COX analyses of overall survival in BC patients

Characteristics	N	Univariate analysis		Multiple analysis
Characteristics	N	HR (95% CI)	p-value	HR (95% CI)	p-value
Age
≤ 45	153	Ref		Ref
> 45	782	1.46 (0.81–2.65)	0.208	1.68 (0.88–3.20)	0.117
Ethnicity^#
Hispanic/Latino	32	Ref		Ref
Not Hispanic/Latino	744	21.83 (0.24–9.29)	0.178	NA	0.965
Pathological stage^#
I/II	707	Ref		Ref
III/IV	239	2.28 (1.45–3.61)	0.000*	1.51 (0.81–2.79)	0.195
Tumor size
T1/T2	797	Ref		Ref
T3/T4	157	1.39 (0.83–2.33)	0.207	0.89 (0.44–1.80)	0.753
Lymph node^#
Negative	444	Ref		Ref
Positive	494	2.04 (1.26–3.30)	0.004*	1.77 (0.97–3.20)	0.061
Distant metastasis^#
Negative	788	Ref		Ref
Positive	18	4.35 (2.16–8.75)	0.000*	2.54 (1.11–5.83)	0.028*
ER status^#
Negative	264	Ref		Ref
Positive	667	1.02 (0.63–1.67)	0.925	0.99 (0.58–1.71)	0.981
PR status^#
Negative	161	Ref		Ref
Positive	772	2.88 (1.17–7.12)	0.022*	2.78 (1.11–6.98)	0.029*
HER2 status^#
Negative	531	Ref		Ref
Positive	162	0.96 (0.54–1.71)	0.891	0.66 (0.34–1.30)	0.230
Molecular subtype
HR positive BC	808	Ref		Ref
HER-2 positive BC	36	2.68 (1.07–6.76)	0.036*	2.24 (0.80–6.30)	0.127
TNBC	91	1.67 (0.90–3.11)	0.104	1.95 (1.01–3.77)	0.047*
Histological subtype^#
Infiltrating ductal BC	655	Ref		Ref
Infiltrating lobular BC	192	0.29 (0.12–0.66)	0.003*	0.42 (0.18–0.99)	0.049*
Mixed BC	24	0.56 (0.14–2.31)	0.426	0.21 (0.03–1.57)	0.129
Medullary BC	3	1.03 (0.25–4.32)	0.963	1.68 (0.39–7.14)	0.484
Metaplastic BC	5	NA	0.977	NA	0.974
Mucinous BC	16	2.18 (0.30–15.85)	0.441	3.86 (0.52–28.64)	0.187
Others	39	1.07 (0.49–2.35)	0.872	0.99 (0.37–2.62)	0.983
FST expression
Low	77	Ref		Ref
High	858	0.47 (0.27–0.82)	0.008*	0.40 (0.21–0.75)	0.004*

^#The composition ratio is less than 100%; *p < 0.05, statistical significance
HR hazard ratio, CI confidence interval, HR positive BC, hormone receptor positive breast cancer; HER-2 positive BC, human epidermalgrowth factor receptor-2 positive breast cancer; TNBC triple-negative breast cancer

ISSN: 1475-2867